Short Interest in NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) Increases By 4,169.8%

NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) saw a significant growth in short interest in the month of October. As of October 31st, there was short interest totalling 764,300 shares, a growth of 4,169.8% from the October 15th total of 17,900 shares. Based on an average daily volume of 2,810,000 shares, the days-to-cover ratio is presently 0.3 days.

NovaBay Pharmaceuticals Stock Performance

NovaBay Pharmaceuticals stock traded up $0.01 during midday trading on Tuesday, reaching $0.72. The stock had a trading volume of 56,890 shares, compared to its average volume of 1,000,580. NovaBay Pharmaceuticals has a twelve month low of $0.36 and a twelve month high of $12.08. The firm has a market capitalization of $3.01 million, a price-to-earnings ratio of -0.07 and a beta of 2.82.

NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) last released its earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($1.37) earnings per share (EPS) for the quarter. NovaBay Pharmaceuticals had a negative return on equity of 146.20% and a negative net margin of 79.70%. The company had revenue of $2.40 million during the quarter. Equities analysts forecast that NovaBay Pharmaceuticals will post -2.54 earnings per share for the current fiscal year.

About NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc develops and sells eyecare and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; Avenova Eye Health Support antioxidant-rich oral supplements; Avenova Lubricating Eye Drops for instant relief; NovaWipes by Avenova; Avenova WarmEye Compress to soothe the eyes; and the i-Chek by Avenova to monitor physical eyelid health.